Front Row Advisors’s Moderna MRNA Stock Holding History

Front Row Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$10.3K	–	682
2023 Q3	$10.3K	Buy	+100	New	+$11.2K	﹤0.01%	509

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Front Row Advisors's MRNA Position: Q4 2023 in Review

Front Row Advisors sold out of Moderna (MRNA) in Q4 2023, closing a stake of 100 shares — an estimated $10.3K sold.

Front Row Advisors first reported a position in MRNA in Q3 2023 and held it in 1 quarter. The position peaked at $10.3K in Q3 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

Front Row Advisors reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
Front Row Advisors sold 100 Moderna shares in Q4 2023, an estimated $10.3K.
Front Row Advisors first reported a position in Moderna in Q3 2023 and held it in 1 quarter.
Front Row Advisors's Moderna position peaked at $10.3K in Q3 2023.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Front Row Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.